Showing 1741-1750 of 5771 results for "".
- Bausch + Lomb and Clearside Biomedical Announce US Commercial Launch of Xiperehttps://modernod.com/news/bausch-lomb-and-clearside-biomedical-announce-us-commercial-launch-of-xipere/2480725/Bausch + Lomb announced the US commercial launch of Xipere (triamcinolone acetonide injectable suspension), the first and only therapy approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis. "Xipere is the first and
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- Show Organizers Announce that Vision Expo+, a Complimentary, Virtual Extension of the Vision Expo Experience Will be Offered April 1–8, 2022https://modernod.com/news/show-organizers-announce-that-vision-expo-a-complimentary-virtual-extension-of-the-vision-expo-experience-will-be-offered-april-1-8-2022/2480715/The Vision Council and RX, co-organizers of Vision Expo, announced that Vision Expo+, a complimentary digital extension of the Vision Expo experience, will be offered from Friday April 1 to Friday, April 8, 2022. Vision Expo+ will be delivered through
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-us-lightsite-iii-clinical-trial-meets-primary-efficacy-endpoint-in-improving-vision-in-dry-amd-patients/2480712/LumiThera announced positive findings in its LIGHTSITE III multicenter clinical trial in non-neovascular (dry) age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked, randomized, multicenter clinica
- Visus Therapeutics Announces Appointment of Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquartershttps://modernod.com/news/visus-therapeutics-announces-appointment-of-julia-williams-as-vice-president-of-clinical-and-medical-affairs-and-expansion-of-irvine-co-headquarters/2480703/Visus Therapeutics announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs. The company also announced the expansion of its Irvine co-headquarters in the University of California-Irvine Research Park, including the establishment
- RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meetinghttps://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- SECO Announces Its 2022 Award Winnershttps://modernod.com/news/seco-announces-its-2022-award-winners/2480691/SECO International announced the recipients of its 2022 awards. The awards recognize leaders in optometry and their significant contributions to the profession. “It is an honor and privilege to recognize this outstanding group of leaders and their contribution to the pr
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure